Statement of Need

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is an immune-mediated neuropathy that is frequently misdiagnosed. The diagnostic process involves correlating electrophysiological data (nerve conduction studies) with clinical features, but misinterpretation of electrophysiologic findings can lead to diagnostic errors. There are also atypical forms of CIDP and alternative diagnoses for demyelinating polyneuropathy that must be considered when clinical features do not align with CIDP. An accurate diagnosis of CIDP is crucial for ensuring that patients receive appropriate and timely treatment and avoid unnecessary interventions. Treatment of CIDP is paramount to preventing disability. Immunosuppressive therapy is the cornerstone of treatment for CIDP, but recently approved novel agents are shifting the CIDP treatment paradigm. Clinicians may not be familiar with these agents and available data related to switching between agents. Evidence also indicates that clinicians lack competency in assessing treatment response and performing dose optimization for maintenance treatment as overtreatment is common. Clinicians require an understanding of available diagnostic tools and approaches to individualized treatment to improve diagnostic precision, therapeutic decision-making, and overall outcomes for patients with CICP.

Target Audience

This activity is intended for neuromuscular disease specialists, neurologists, specialty nurse practitioners, specialty physician assistants, specialty nurses who treat CIDP, primary care physicians, orthopedic specialists, internists, clinical, specialty and managed care pharmacists and other non-specialist HCPs.

Learning Objectives

Upon completion of this activity, participants will be able to:

• Develop appropriate clinical protocols using clinical, electrodiagnostic, and supportive CIDP diagnostic criteria to mitigate barriers for timely diagnosis and initiation of therapy
• Explain the immunopathologic mechanisms driving CIDP and the therapeutic rationale for neonatal Fc receptor (FcRn) antagonism to inform individualized treatment decisions
• Review the latest clinical trial data supporting recently approved and emerging CIDP therapies and assess readiness to introduce novel therapies into evolving treatment paradigms
• Select patients with CIDP who may benefit from FcRn antagonists based on disease characteristics, treatment history, and response predictors
• Develop individualized treatment strategies that incorporate patient preferences, dosing considerations, and real-world evidence

Method of Participation

To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view the online interventions; and return after 30 days to report progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.

ABIM credit will be submitted to ABIM within 30 days of completion. CPE credit will be submitted to CPE Monitor^® on the first business day of each month. Partial credit may not be awarded for CBRN credit; participation in the complete activity is required to receive credit.

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Accreditation and Credit Designation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.5 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

By providing your ABIM Diplomate number, you consent to have ACHL and/or our educational partners submit your participation in this activity to the ABIM through the ACCME PARS system. ABIM credit will be submitted to PARS on the first day of each month.

Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

Provider approved by the California Board of Registered Nursing, Provider Number 17273 for 2.5 contact hours.

Disclosures

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.

The following financial relationships have been provided:

Jeffrey Allen, MD
Consulting Agreement: Alexion, Alnylam, Annexon, Argenx, Astra Zeneca, CSL Behring, Dianthus, Grifols, ImmunoPharma, Immunovant, Johnson and Johnson, Sanofi, Takeda

Karissa Gable, MD
Adjudication Committee: Dianthus, Immunovant, Sanofi
Advisory Board: Argenx, Sanofi
Consulting Agreement: Argenx, CSL Behring, Dianthus, Grifols, Immunovant, In Circle, Sanofi

Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose.

Staff and Reviewer Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Disclaimer

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: intravenous or subcutaneous immunoglobulin, plasma exchange, rituximab, corticosteroids, nipocalimab, riliprubart, and other immunosuppressive agents.

Acknowledgement

Provided by the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an independent educational grant from argenx US Inc.